Novo Nordisk Ends Collaboration With Hims & Hers Over Weight Loss Drug Sale

Reuters
23 Jun

COPENHAGEN, June 23 (Reuters) - Novo Nordisk said on Monday it would halt its collaboration with Hims & Hers Health over the sale of weight loss drugs.

The two companies had announced a collaboration in April for Hims & Hers to sell Novo's blockbuster Wegovy weight loss drug through a bundled offering on the telehealth company's platform.

Novo Nordisk said in a statement on Monday that direct access to Wegovy would no longer be available to Hims & Hers Health via the NovoCare Pharmacy.

Hims & Hers shares plunged 18% on the news.

Novo Nordisk shares dropped 5.6% in premarket.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10